Market Place
Sourcing Support
Sage Therapeutics Announces Phase 2 Results for Dalzanemdor
20 Nov 2024 //
BUSINESSWIRE
Sage discontinues Zulresso, drops pair of pipeline prospects
30 Oct 2024 //
FIERCE PHARMA
Sage Therapeutics Reveals Q3 2024 Financial Results and Pipeline
29 Oct 2024 //
BUSINESSWIRE
Sage lays off half of R&D team, shakes up C-suite again
18 Oct 2024 //
FIERCE BIOTECH
Sage Announces Strategic Reorganization to Prioritize Zurzuvae
17 Oct 2024 //
BUSINESSWIRE
Sage to Report Third Quarter 2024 Financial Results on Oct 29, 2024
15 Oct 2024 //
BUSINESSWIRE
Sage Therapeutics scraps Alzheimer’s drug after trial fails
09 Oct 2024 //
REUTERS
Biogen cans SAGE-324 collaboration after essential tremor fail
27 Sep 2024 //
FIERCE BIOTECH
Sage Therapeutics Ends Biogen Collaboration On SAGE-324
26 Sep 2024 //
BUSINESSWIRE
Sage Therapeutics Reports Q2 2024 Results And Pipeline Updates
31 Jul 2024 //
BUSINESSWIRE
Biogen, Sage Scrap Essential Tremor Study After Phase II Failure
24 Jul 2024 //
PRESS RELEASE
Sage Therapeutics To Report Q2 2024 Financials On July 31
17 Jul 2024 //
BUSINESSWIRE
Sage`s dalzanemdor trial design leaves efficacy question unclear
11 Jun 2024 //
FIERCE BIOTECH
Sage Therapeutics: Presenting At Goldman Sachs Healthcare Event
05 Jun 2024 //
BUSINESSWIRE
FDA Approves Oral Treatment for Postpartum Depression
08 May 2024 //
DRUGTOPICS
Sage Therapeutics to Participate in Upcoming May Investor Conferences
07 May 2024 //
BUSINESSWIRE
Sage Therapeutics Q1 2024 Results, Pipeline/Business Progress
25 Apr 2024 //
BUSINESSWIRE
Sage focuses on successful launch of postpartum depression drug
25 Apr 2024 //
ENDPTS
Sage Axes Parkinson’s Program for Dalzanemdor After Phase II Flop
18 Apr 2024 //
REUTERS
Sage Therapeutics Q1 2024 Results On 4/25
11 Apr 2024 //
BUSINESSWIRE
Sage Therapeutics to Present at Upcoming March Investor Conferences
28 Feb 2024 //
BUSINESSWIRE
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
14 Feb 2024 //
BUSINESSWIRE
Sage `highly encouraged` by Zurzuvae launch with Biogen
14 Feb 2024 //
FIERCE PHARMA
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
31 Jan 2024 //
BUSINESSWIRE
After 40% reduction in workforce, Sage will shift to smaller HQ
25 Jan 2024 //
FIERCE PHARMA
Sage Therapeutics Announces Changes to Board of Directors
08 Jan 2024 //
BUSINESSWIRE
Sage to Provide Business Updates at 42nd Annual J.P. Morgan Conference
08 Jan 2024 //
BUSINESSWIRE
Sage Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
ZURZUVAE a Landmark Oral Treatment for PPD, is Now Available in the U.S.
14 Dec 2023 //
GLOBENEWSWIRE
Sage Therapeutics to Present at Upcoming November Investor Conferences
08 Nov 2023 //
BUSINESSWIRE
Sage Therapeutics Announces Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900
07 Nov 2023 //
REUTERS
Sage, Biogen call an audible on pricing strategy for Zurzuvae
07 Nov 2023 //
FIERCE PHARMA
Sage Therapeutics to Report Third Quarter 2023 Financial Results
24 Oct 2023 //
BUSINESSWIRE
Sage Therapeutics Announces FDA Granted SAGE-718 Orphan Drug Designation
18 Oct 2023 //
BUSINESSWIRE
Sage Therapeutics to Present at Upcoming September Investor Conferences
06 Sep 2023 //
BUSINESSWIRE
FDA documents hint ‘uphill battle’ for broad approval of Sage’s depression drug
02 Sep 2023 //
BIOPHARMADIVE
Sage shrinks workforce by 40% in light of major depression drug rejection
01 Sep 2023 //
ENDPTS
Sage considers cuts after FDA’s split decision on depression drug
08 Aug 2023 //
BIOPHARMADIVE
Sage Therapeutics Announces Second Quarter 2023 Financial Results
07 Aug 2023 //
BUSINESSWIRE
US FDA approves Biogen-Sage Therapeutics pill for postpartum depression
05 Aug 2023 //
REUTERS
Sage Therapeutics to Announce Q2 Financial Results on Monday, August 7, 2023
04 Aug 2023 //
BUSINESSWIRE
Why Sage Therapeutics Stock Is Tumbling Today
26 Jul 2023 //
FOOL
Sage to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
05 Jun 2023 //
BUSINESSWIRE
Sage Therapeutics Announces 1Q 2023 FYR and Highlights Pipeline
02 May 2023 //
BUSINESSWIRE
Sage Therapeutics to Report1Q2023 Financial Results on Tuesday, May 2, 2023
18 Apr 2023 //
BUSINESSWIRE
Sage Therapeutics to Present at the Stifel 2023 CNS Days
22 Mar 2023 //
BUSINESSWIRE
Sage Therapeutics Appoints Jessica Federer to Board of Directors
16 Mar 2023 //
BUSINESSWIRE
FDA says no adcomm planned for Biogen, Sage`s depression drug
09 Mar 2023 //
ENDPTS
Sage Therapeutics & Biogen Share Update on FDA Advisory Committee for Zuranolone
08 Mar 2023 //
BUSINESSWIRE
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
BUSINESSWIRE
Sage Announces EMA Granted SAGE-718 Orphan Drug Designation
22 Feb 2023 //
BUSINESSWIRE
Sage Therapeutics Announces Fourth Quarter 2022 Financial Results
16 Feb 2023 //
BUSINESSWIRE
Eliem axes depression drug, lays off 55% of team to stretch cash
11 Feb 2023 //
FIERCE BIOTECH
Biogen and Sage Announce FDA Grants Priority Review of Zuranolone
06 Feb 2023 //
PRESS RELEASE
Sage Therapeutics to Report Q4 and Full Year 2022 Financial Results
02 Feb 2023 //
BUSINESSWIRE
JPM23: Sage CEO says postpartum depression is no niche market
10 Jan 2023 //
FIERCEBIOTECH
Sage to Provide Update on 2023 Initiatives at J.P. Morgan Healthcare Conference
08 Jan 2023 //
BUSINESSWIRE
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Biogen and Sage Therapeutics Complete Rolling Submission of NDA for Zuranolone
06 Dec 2022 //
PRESS RELEASE
